Key Takeaways
- • Adenia Partners closed its Entrepreneurial Fund I at a $180 million hard cap, exceeding its original $150 million target within less than a year, targeting control investments in small and lower mid-cap African companies.
- • SPE Capital-led consortium completed an investment in Egypt's Orchidia Pharmaceutical Industries through SPE Capital's Private Equity Fund III, alongside co-investors including the European Bank for Reconstruction and Development and Proparco, expanding healthcare-focused private capital activity in North Africa.
- • Phatisa and AgDevCo exited their stake in Goldenlay, Zambia's largest table-egg producer, selling the majority position to Belgium-based Vanden Avenne Group in a transaction with undisclosed financial terms, marking a significant agricultural sector exit in Southern Africa.
- • Q1 2026 exit activity remained in line with three-year averages, with 25 exits recorded—a 1.5x year-over-year increase—indicating stabilization in African private equity exit pathways following pandemic-related disruptions.
- • Q2 2026 recorded seven exits, the lowest quarterly count since Q4 2022, with the SVL (Strategic Value and Liquidity) Index falling to 82.46 below long-run averages, signaling tightening exit conditions mid-year.
Summary
African private equity activity in 2026 demonstrated mixed momentum, with notable fundraising success offset by declining exit velocity in the second half of the year. The March 2026 period captured significant transaction activity across multiple sectors and geographies, reflecting ongoing investor appetite for small and mid-cap control investments despite structural challenges in exit pathways.
Adenia Partners achieved an early milestone with its Entrepreneurial Fund I reaching hard cap at $180 million, representing a 20% oversubscription relative to its initial $150 million target. The fund's rapid capital deployment underscores institutional confidence in the small and lower mid-cap segment, characterized as the continent's largest yet most undercapitalized private sector cohort. This fundraising outcome signals sustained investor appetite for control-oriented strategies targeting companies below the traditional mid-market focus of larger African funds.
Pharmaceutical and agricultural sectors emerged as key exit and investment focal points. SPE Capital's consortium completed an investment in Orchidia Pharmaceutical Industries, an Egyptian eye-care medicines manufacturer, marking multilateral development finance involvement through the European Bank for Reconstruction and Development and Proparco. Simultaneously, Phatisa and AgDevCo exited Goldenlay, Zambia's largest table-egg producer, via a majority stake sale to Belgian integrated feed and protein manufacturer Vanden Avenne Group. The Goldenlay transaction—involving a fully integrated producer combining production, upstream feed farming, and nationwide distribution—exemplifies the agricultural value-add investment thesis prevalent in Southern African private capital markets.
However, exit data from Q2 2026 revealed pronounced market tightening, with only seven recorded exits representing the lowest quarterly count since Q4 2022. The SVL Index declined to 82.46, below historical averages, indicating structural liquidity constraints. This contrasts sharply with Q1's 25 exits—a 1.5x year-over-year increase—suggesting uneven exit velocity across quarters. Market participants continue confronting the endemic "exit challenge," with limited public market pathways; among 33 reported African private equity exits in the prior year, zero occurred through initial public offerings, constraining institutional exit optionality and reinforcing reliance on strategic buyer and secondary transactions.
Adenia Partners achieved an early milestone with its Entrepreneurial Fund I reaching hard cap at $180 million, representing a 20% oversubscription relative to its initial $150 million target. The fund's rapid capital deployment underscores institutional confidence in the small and lower mid-cap segment, characterized as the continent's largest yet most undercapitalized private sector cohort. This fundraising outcome signals sustained investor appetite for control-oriented strategies targeting companies below the traditional mid-market focus of larger African funds.
Pharmaceutical and agricultural sectors emerged as key exit and investment focal points. SPE Capital's consortium completed an investment in Orchidia Pharmaceutical Industries, an Egyptian eye-care medicines manufacturer, marking multilateral development finance involvement through the European Bank for Reconstruction and Development and Proparco. Simultaneously, Phatisa and AgDevCo exited Goldenlay, Zambia's largest table-egg producer, via a majority stake sale to Belgian integrated feed and protein manufacturer Vanden Avenne Group. The Goldenlay transaction—involving a fully integrated producer combining production, upstream feed farming, and nationwide distribution—exemplifies the agricultural value-add investment thesis prevalent in Southern African private capital markets.
However, exit data from Q2 2026 revealed pronounced market tightening, with only seven recorded exits representing the lowest quarterly count since Q4 2022. The SVL Index declined to 82.46, below historical averages, indicating structural liquidity constraints. This contrasts sharply with Q1's 25 exits—a 1.5x year-over-year increase—suggesting uneven exit velocity across quarters. Market participants continue confronting the endemic "exit challenge," with limited public market pathways; among 33 reported African private equity exits in the prior year, zero occurred through initial public offerings, constraining institutional exit optionality and reinforcing reliance on strategic buyer and secondary transactions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.